Fatty Acids: Structures and Introductory Article Properties Article Contents
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Role of Short Chain Fatty Acids in Appetite Regulation and Energy Homeostasis
OPEN International Journal of Obesity (2015) 39, 1331–1338 © 2015 Macmillan Publishers Limited All rights reserved 0307-0565/15 www.nature.com/ijo REVIEW The role of short chain fatty acids in appetite regulation and energy homeostasis CS Byrne1, ES Chambers1, DJ Morrison2 and G Frost1 Over the last 20 years there has been an increasing interest in the influence of the gastrointestinal tract on appetite regulation. Much of the focus has been on the neuronal and hormonal relationship between the gastrointestinal tract and the brain. There is now mounting evidence that the colonic microbiota and their metabolic activity have a significant role in energy homeostasis. The supply of substrate to the colonic microbiota has a major impact on the microbial population and the metabolites they produce, particularly short chain fatty acids (SCFAs). SCFAs are produced when non-digestible carbohydrates, namely dietary fibres and resistant starch, undergo fermentation by the colonic microbiota. Both the consumption of fermentable carbohydrates and the administration of SCFAs have been reported to result in a wide range of health benefits including improvements in body composition, glucose homeostasis, blood lipid profiles and reduced body weight and colon cancer risk. However, published studies tend to report the effects that fermentable carbohydrates and SCFAs have on specific tissues and metabolic processes, and fail to explain how these local effects translate into systemic effects and the mitigation of disease risk. Moreover, studies tend to investigate SCFAs collectively and neglect to report the effects associated with individual SCFAs. Here, we bring together the recent evidence and suggest an overarching model for the effects of SCFAs on one of their beneficial aspects: appetite regulation and energy homeostasis. -
Fatty Acids and Risk of Prostate Cancer in a Nested Case-Control Study in Male Smokers
1422 Vol. 12, 1422–1428, December 2003 Cancer Epidemiology, Biomarkers & Prevention Fatty Acids and Risk of Prostate Cancer in a Nested Case-Control Study in Male Smokers Satu Ma¨nnisto¨,1,3 Pirjo Pietinen,1 Mikko J. Virtanen,1 serum or dietary ␣-linolenic acid or any other Irma Salminen,2 Demetrius Albanes,5 unsaturated fatty acid and prostate cancer risk, but high Edward Giovannucci,3,4,6 and Jarmo Virtamo1 serum linoleic acid was associated with lower risk in men ␣ Departments of 1Epidemiology and Health Promotion, and 2Health and supplemented with -tocopherol. High serum myristic Functional Capacity, National Public Health Institute, Helsinki, Finland; acid associated with an increased risk of prostate cancer. Departments of 3Nutrition and 4Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 5National Cancer Institute, NIH, Bethesda, Maryland; and 6Department of Medicine, Harvard Medical School, Boston, Introduction Massachusetts Migrant studies and ecologic evidence that incidence rates of clinical prostate cancer vary geographically much more than Abstract that of latent prostate cancer suggest that environmental factors play an important role at least in late prostatic carcinogenesis There is some evidence that ␣-linolenic acid might be (1). Some dietary factors especially have been observed to positively related to prostate cancer risk. Associations increase prostate cancer risk (2). between serum fatty acid composition as well as fatty The evidence on an association between fat intake and acid intakes and prostate cancer risk were examined in prostate cancer risk is mainly based on epidemiological studies. the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Most case-control studies have associated high intakes of ani- Study. -
Stearic Acid Acceptance Criteria: 194–212 Portions of This Monograph That Are National USP Text, and • C
Stage 6 Harmonization Official May 1, 2016 Stearic 1 L . = molecular weight of potassium hydroxide, Mr 56.11LNF34 Stearic Acid Acceptance criteria: 194±212 Portions of this monograph that are national USP text, and • C. The retention times of the major peaks of the Sample are not part of the harmonized text, are marked with solution correspond to those of the Standard solution, as N symbols ( .N) to specify this fact. obtained in the Assay. Octadecanoic acid; ASSAY Stearic acid [57-11-4]. • PROCEDURE DEFINITION Boron trifluoride±methanol solution: 140 g/L of bo- ron trifluoride in methanol Sample solution: Dissolve 100 mg of Stearic Acid in a Change to read: small conical flask fitted with a suitable reflux attach- ment with 5 mL of Boron trifluoride±methanol solution. Mixture consisting of stearic (octadecanoic) acid (C18H36O2; Boil under reflux for 10 min. Add 4.0 mL of heptane Mr, 284.5) and palmitic (hexadecanoic) acid (C16H32O2; through the condenser, and boil again under reflux for Mr, 256.4) obtained from fats or oils of vegetable or 10 min. Allow to cool. Add 20 mL of a saturated solu- animal origin. tion of sodium chloride. Shake, and allow the layers to Content: separate. Remove about 2 mL of the organic layer, and dry it over 0.2 g of anhydrous sodium sulfate. Dilute 1.0 mL of this solution with heptane to 10.0 mL. Stearic acid: 40.0%±60.0%. Sum of the Standard solution: Prepare as directed in the Sample contents of stearic acid and palmitic acids: solution using 50 mg of USP Stearic Acid RS and 50 mg Stearic acid 50 NLT 90.0%. -
Fatty Acid Diets: Regulation of Gut Microbiota Composition and Obesity and Its Related Metabolic Dysbiosis
International Journal of Molecular Sciences Review Fatty Acid Diets: Regulation of Gut Microbiota Composition and Obesity and Its Related Metabolic Dysbiosis David Johane Machate 1, Priscila Silva Figueiredo 2 , Gabriela Marcelino 2 , Rita de Cássia Avellaneda Guimarães 2,*, Priscila Aiko Hiane 2 , Danielle Bogo 2, Verônica Assalin Zorgetto Pinheiro 2, Lincoln Carlos Silva de Oliveira 3 and Arnildo Pott 1 1 Graduate Program in Biotechnology and Biodiversity in the Central-West Region of Brazil, Federal University of Mato Grosso do Sul, Campo Grande 79079-900, Brazil; [email protected] (D.J.M.); [email protected] (A.P.) 2 Graduate Program in Health and Development in the Central-West Region of Brazil, Federal University of Mato Grosso do Sul, Campo Grande 79079-900, Brazil; pri.fi[email protected] (P.S.F.); [email protected] (G.M.); [email protected] (P.A.H.); [email protected] (D.B.); [email protected] (V.A.Z.P.) 3 Chemistry Institute, Federal University of Mato Grosso do Sul, Campo Grande 79079-900, Brazil; [email protected] * Correspondence: [email protected]; Tel.: +55-67-3345-7416 Received: 9 March 2020; Accepted: 27 March 2020; Published: 8 June 2020 Abstract: Long-term high-fat dietary intake plays a crucial role in the composition of gut microbiota in animal models and human subjects, which affect directly short-chain fatty acid (SCFA) production and host health. This review aims to highlight the interplay of fatty acid (FA) intake and gut microbiota composition and its interaction with hosts in health promotion and obesity prevention and its related metabolic dysbiosis. -
Blood Fats Explained
Blood Fats Explained HEART UK – The Cholesterol Charity providing expert support, education and influence 2 | Fats in the blood At risk of cardiovascular disease? | 3 Fats in the blood At risk of cardiovascular disease? Fats that circulate in the blood are called lipids. Very low density lipoproteins (VLDL) transport Cardiovascular disease (CVD) is the medical Blood pressure is a measure of the resistance Cholesterol and triglycerides are both lipids. mainly triglycerides made by the liver to where name for circulatory diseases such as coronary to the flow of blood around your body. It is They have essential roles in the body. In excess they are either used to fuel our muscles or stored heart disease (CHD), stroke, mini stroke (transient measured in millimetres of mercury (mmHg). Your they are harmful. for later use. ischaemic attack or TIA), angina and peripheral doctor or nurse will measure both your systolic vascular disease (PVD). You are more likely to (upper figure) and diastolic (lower figure) blood Cholesterol is needed to build cell walls and Low density lipoproteins (LDL) carry most of the develop CVD the more risk factors you have. pressure. About a third of adults have high blood to make hormones and vitamin D. Some of our cholesterol in our body from the liver to the cells pressure. If untreated it increases the risk of cholesterol comes from the food we eat; but most that need it. The cholesterol that is carried on LDLs There are two types of risk factors: heart attack and stroke. High blood pressure is is made in the liver. -
Effects of Butter Oil Blends with Increased Concentrations of Stearic, Oleic and Linolenic Acid on Blood Lipids in Young Adults
European Journal of Clinical Nutrition (1999) 53, 535±541 ß 1999 Stockton Press. All rights reserved 0954±3007/98 $12.00 http://www.stockton-press.co.uk/ejcn Effects of butter oil blends with increased concentrations of stearic, oleic and linolenic acid on blood lipids in young adults CC Becker1, P Lund1, G Hùlmer1*, H Jensen2 and B SandstroÈm2 1Department of Biochemistry and Nutrition, Center for Food Research, Technical University of Denmark, Denmark; and 2Research Department of Human Nutrition, Center for Food Research, The Royal Veterinary and Agricultural University, Frederiksberg, Denmark Objective: The aim of this present project was to evaluate a more satisfactory effect on plasma lipoprotein pro®le of spreads based on dairy fat. Design: This study was designed as a randomised cross-over experiment with a three-week treatment separated by a three-week wash-out period. Sixty ®ve grams of the fat content of the habitual diets was replaced by either butter=grapeseed oil (90 : 10) (BG); butter oil and low erucic rapeseed oil (65 : 35) (BR) or butter blended in a 1 : 1 ratio with a interesteri®ed mixture of rapeseed oil and fully hydrogenated rapeseed oil (70 : 30) (BS). Subjects: Thirteen healthy free-living young men (age 21±26 y) ful®lled the study. Interventions: At the beginning and end of each diet period two venous blood samples were collected. Triacylglycerol and cholesterol concentrations in total plasma and VLDL, LDL, IDL and HDL fractions were measured, as were apo A-1 and apo B concentrations. Fatty acid composition of plasma phospholipids, plasma cholesterol ester and platelets was also determined. -
Free Fatty Acids Are Associated with the Cognitive Functions in Stroke Survivors
International Journal of Environmental Research and Public Health Article Free Fatty Acids Are Associated with the Cognitive Functions in Stroke Survivors Dariusz Kotl˛ega 1,* , Barbara Peda 1, Joanna Palma 2 , Agnieszka Zembro ´n-Łacny 3 , Monika Goł ˛ab-Janowska 4, Marta Masztalewicz 4, Przemysław Nowacki 4 and Małgorzata Szczuko 2 1 Department of Neurology, District Hospital, 67-200 Glogow, Poland; [email protected] 2 Department of Human Nutrition and Metabolomics, Pomeranian Medical University, 71-460 Szczecin, Poland; [email protected] (J.P.); [email protected] (M.S.) 3 Department of Applied and Clinical Physiology, Collegium Medicum, University of Zielona Gora, 65-001 Zielona Góra, Poland; [email protected] 4 Department of Neurology, Pomeranian Medical University, 71-252 Szczecin, Poland; [email protected] (M.G.-J.); [email protected] (M.M.); [email protected] (P.N.) * Correspondence: [email protected] Abstract: Ischemic stroke is a leading cause of motor impairment and psychosocial disability. Al- though free fatty acids (FFA) have been proven to affect the risk of stroke and potentially dementia, the evidence of their impact on cognitive functions in stroke patients is lacking. We aimed to establish such potential relationships. Seventy-two ischemic stroke patients were prospectively analysed. Their cognitive functions were assessed seven days post-stroke and six months later as follow-up (n = 41). Seven days post-stroke analysis of serum FFAs levels showed direct correlations between Citation: Kotl˛ega,D.; Peda, B.; Cognitive Verbal Learning Test (CVLT) and the following FFAs: C20:4n6 arachidonic acid and Palma, J.; Zembro´n-Łacny, A.; C20:5n3 eicosapentaenoic acid, while negative correlations were observed for C18:3n3 linolenic acid Goł ˛ab-Janowska,M.; Masztalewicz, (ALA), C18:4 n3 stearidonic acid and C23:0 tricosanoic acid. -
Fatty Acids: Essential…Therapeutic
Volume 3, No.2 May/June 2000 A CONCISE UPDATE OF IMPORTANT ISSUES CONCERNING NATURAL HEALTH INGREDIENTS Written and Edited By: Thomas G. Guilliams Ph.D. FATTY ACIDS: Essential...Therapeutic Few things have been as confusing to both patient and health care provider as the issue of fats and oils. Of all the essential nutrients required for optimal health, fatty acids have not only been forgotten they have been considered hazardous. Health has somehow been equated with “low-fat” or “fat-free” for so long, to suggest that fats could be essential or even therapeutic is to risk credibility. We hope to give a view of fats that is both balanced and scientific. This review will cover the basics of most fats that will be encountered in dietary or supplemental protocols. Recommendations to view essential fatty acids in a similar fashion as essential vitamins and minerals will be combined with therapeutic protocols for conditions ranging from cardiovascular disease, skin conditions, diabetes, nerve related disorders, retinal disorders and more. A complete restoration of health cannot be accomplished until there is a restoration of fatty acid nutritional information among health care professionals and their patients. Fats- What are they? Dietary fats come to us from a variety of sources, but primarily in the form of triglycerides. That is, three fatty acid molecules connected by a glycerol backbone (see fatty acid primer page 3 for diagram). These fatty acids are then used as energy by our cells or modified into phospholipids to be used as cell or organelle membranes. Some fatty acids are used in lipoprotein molecules to shuttle cholesterol and fats to and from cells, and fats may also be stored for later use. -
Omega-3 Eicosapentaenoic Acid (EPA)
nutrients Article Omega-3 Eicosapentaenoic Acid (EPA) Rich Extract from the Microalga Nannochloropsis Decreases Cholesterol in Healthy Individuals: A Double-Blind, Randomized, Placebo-Controlled, Three-Month Supplementation Study Amanda Rao 1,2 , David Briskey 1,3, Jakob O Nalley 4 and Eneko Ganuza 4,* 1 RDC Clinical, Brisbane 4006, Australia; [email protected] (A.R.); [email protected] (D.B.) 2 School of Medicine, University of Sydney, Sydney, NSW 2006, Australia 3 School of Human Movement and Nutrition Sciences, The University of Queensland, Brisbane, QLD 4067, Australia 4 Qualitas Health, Houston, TX 77056, USA; [email protected] * Correspondence: [email protected] Received: 26 May 2020; Accepted: 20 June 2020; Published: 23 June 2020 Abstract: The aim of this trial is to assess the effect of Almega®PL on improving the Omega-3 Index, cardio-metabolic parameters, and other biomarkers in generally healthy individuals. The benefits of long-chain omega-3 fatty acids for cardiovascular health are primarily built upon mixtures of docosahexaenoic (DHA) and eicosapentaenoic acids (EPA). Highly purified EPA therapy has proven to be particularly effective in the treatment of cardiovascular disease, but less is known about the benefits of EPA-only supplementation for the general healthy population. Almega®PL is a polar rich oil (>15%) derived from the microalga Nannochloropsis that contains EPA (>25%) with no DHA. Participants (n = 120) were given a capsule of 1 g/day of either Almega®PL or placebo for 12 weeks. Differences in the Omega-3 Index, cardiometabolic markers, and other general health indicators were measured at the baseline, six, and 12 weeks. -
Effects of Dietary Fats on Blood Lipids: a Review of Direct Comparison Trials
Open access Editorial Open Heart: first published as 10.1136/openhrt-2018-000871 on 25 July 2018. Downloaded from Effects of dietary fats on blood lipids: a review of direct comparison trials James J DiNicolantonio, James H O’Keefe To cite: DiNicolantonio JJ, INTRODUCTION very LDL (VLDL) and HDL are also inconsis- O’Keefe JH. Effects of dietary Saturated fat has been demonised as a dietary tent.11 Thus, it is impossible to know what the fats on blood lipids: a review of overall health impact is when saturated fat is direct comparison trials. Open culprit in heart disease due to its ability to Heart 2018;5:e000871. raise low-density lipoprotein cholesterol replaced with omega-6 PUFA. doi:10.1136/ (LDL-C), whereas omega-6 polyunsaturated openhrt-2018-000871 fatty acid (PUFA) has been regarded as MONOUNSATURATED FAT VERSUS SATURATED heart healthy due to its ability to lower total FAT Accepted 3 July 2018 and LDL-C. And replacing saturated fat with Monounsaturated fat ((MUFA) such as oleic omega-6 has consistently been found to lower 1 2 acid, which is found in olive oil, has classically total cholesterol and LDL-C levels. This has been thought of as being heart healthy as been the cornerstone for the belief that the olive oil is the main dietary fat used in the omega-6 PUFA linoleic acid is heart healthy. Mediterranean region, which is well known However, the changes in LDL-C do not take for its low risk for cardiovascular disease. into account the overall changes in the entire Meals high in both MUFA and satu- lipoprotein profile. -
Eicosapentaenoic Acid (EPA) Reduces Cardiovascular Events: Relationship with the EPA/Arachidonic Acid Ratio
Advance Publication Journal of AtherosclerosisJournal and Thrombosis of Atherosclerosis Vol.20, No.● and Thrombosis1 Review Accepted for publication: June 17, 2013 Published online: September 18, 2013 Eicosapentaenoic Acid (EPA) Reduces Cardiovascular Events: Relationship with the EPA/Arachidonic Acid Ratio Haruo Ohnishi1 and Yasushi Saito2 1Mochida Pharmaceutical Co. Ltd., Tokyo, Japan 2Chiba University Graduate School of Medicine, Chiba, Japan The clinical efficacy of fish oil and high-purity eicosapentaenoic acid ethyl ester (hp-EPA-E) for treat- ing cardiovascular disease (CVD) has been reported. Fish oil contains saturated and monounsatu- rated fatty acids that have pharmacological effects opposite to those of ω3 fatty acids (ω3). Moreover, ω3, such as EPA and docosahexaenoic acid (DHA), do not necessarily have the same metabolic and biological actions. This has obscured the clinical efficacy of ω3. Recently, the Japan EPA Lipid Inter- vention Study (JELIS) of hp-EPA-E established the clinical efficacy of EPA for CVD, and higher lev- els of blood EPA, not DHA, were found to be associated with a lower incidence of major coronary events. A significant reduction in the risk of coronary events was observed when the ratio of EPA to arachidonic acid (AA) (EPA/AA) was >0.75. Furthermore, the ratio of prostaglandin (PG) I3 and PGI2 to thromboxane A2 (TXA2) ([PGI2+PGI3]/TXA2) was determined to have a linear relationship with the EPA/AA ratio as follows: (PGI2+PGI3)/TXA2 =λ+π* (EPA/AA). Like PGI2, PGI3 not only inhib- its platelet aggregation and vasoconstriction, but also is assumed to reduce cardiac ischemic injury and arteriosclerosis and promote angiogenesis. -
Essential Fatty Acid Formulas — — — Liquids
To contact Designs for Health, please call us at (800) 847-8302, or visit us on the web at at (800)847-8302,or visit usontheweb please call Health, usat Designs for contact To These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cureor prevent any disease. treat, These products arenotintended todiagnose, Administration. and Drug These statements havenotbeen evaluatedbytheFood Product Comparison Chart OmegAvail™ OmegAvail™ OmegAvail™ OmegAvail™ OmegAvail™ OmegAvail™ OmegAvail™ OmegAvail™ OmegAvail™ Ultra Ultra Lemon Drop Synergy TG1000 Hi-Po Ultra Marine Liquid with D3, K1 & K2 DHA Smoothie Unique omega-3-6-7-9 High potency DHA/EPA Great for children and fatty acid formula High potency EPA/DHA formula with flexible Highest potency High potency EPA/ Added D3, K1, K2 for Maintenance and High potency DHA the elderly who prefer offers balanced doses in a single softgel for dosing; ideal for EPA/DHA for most DHA for aggressive cardiovascular & bone general omega-3 formula for therapeutic not to take pills, higher of EPA, DHA, GLA, optimal compliance of children, the elderly & aggressive applications applications and immune support dosing DHA applications dosing is easy with palmitoleic acid, and therapeutic dosing those who prefer not to liquids oleic acid swallow pills Serving Size 2 Softgels 1 Softgel 2 Softgels 2 Softgels 2 Softgels 2 Softgels 1 Softgel 11 g (2 tsp.) 5ml (1 tsp.) EPA (n-3) 270 mg 662 mg 1000 mg 600 mg 600 mg 320 mg 110 mg 1100 mg 725 mg DHA (n-3) 180 mg 250 mg 500 mg 400 mg 400 mg 200 mg 500 mg 720 mg 450 mg Other EFAs 645 mg 88 mg — 200 mg 200 mg 80 mg — 230 mg 180 mg Vitamin D3 — — — — 1000 IU — — — — Vitamin K1/K2 — — — — 500 mcg/25 mcg — — — — www.designsforhealth.com Lipase Yes Yes Yes Yes Yes Yes Yes — — For EveryPatient Essential FattyAcidFormulas SPECIAL FORMULAS The Impact of Fatty Acids Fatty acids have a number of fundamental benefits for human health.